SECAUCUS, N.J., Jan. 30, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that it has been selected as one of the 2025 World's Most Admired Companies™ by Fortune® magazine, the 11th consecutive year the company has been named to the elite list of globally respected companies.
The selection is based on nine key attributes related to corporate reputation, including quality of products and services, innovation, community responsibility, social responsibility, and talent management.
"Every day, the more than 55,000 colleagues of Quest Diagnostics bring our purpose to life: working together to create a healthier world, one life at a time," said Jim Davis, Chairman, CEO and President. "Their commitment to living our purpose in service to our customers and patients is the reason we continue to be recognized among Fortune's World's Most Admired Companies."
In addition to the overall ranking, Quest was number three in the "Health Care: Pharmacy and Other Services" industry category. Quest ranked in the top 1 or 2 spot of seven of nine criteria that comprise the industry category, including quality of management, long-term investment, product and service quality, social responsibility and people management.
Consulting firm Korn Ferry collaborated with Fortune to survey thousands of executives, directors and analysts who rated companies in their industry on nine criteria, analyzing a total of 650 companies. A company's score must rank in the top half of its industry survey to be listed as a World's Most Admired Company.
Find more information on the 2025 Fortune's World's Most Admired Companies here.
About Quest Diagnostics
Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our more than 55,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world. www.QuestDiagnostics.com.
Last Trade: | US$168.73 |
Daily Change: | 0.80 0.48 |
Daily Volume: | 853,856 |
Market Cap: | US$18.840B |
July 29, 2025 July 22, 2025 July 15, 2025 June 10, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load